The global non-opioid pain patches market is anticipated to grow at a significant CAGR of around 4.5% during the forecast years. The pain patches are used for the treatment of chronic pain. In these, the medication is infused into the patches that adhere to the skin, the medication enters the body through the skin blocking the pain signals from nerves. The pain patches are majorly used in the treatment of chronic neuropathic neck and back pain. 

The Global Transgenic Seeds market is anticipated to grow at a considerable CAGR of around 7.5% during the forecast period (2022-2028). Transgenic seeds or genetically modified seeds hold future technology promises with their advantages and benefits. Many companies such as Bayer AG, BASF SE, Syngenta among others, or manufacturers of these seeds are investing s to launch several transgenic seeds that are having various benefits and novel traits. ) For instance, in August 2021, Corteva Inc., launched a new genetically modified soybean seed Conkesta E3  in Brazil. The product gotapproval from the European Union Commission along with permission to crop produced by Conkesta E3 soybean seeds to be sold in European market for food and feed use.

The global neprilysin market is expected to grow at a considerable CAGR during the forecast years. Neprilysin inhibitors are the medicines used for the treatment of high blood pressure, Alzheimer’s disease, heart failure, and cancer pain. The reason for the growth of the market is the increasing demand for neprilysin for the treatment of pain in cancer patients. The increasing number of cancer patients is increasing the demand for neprilysin. According to a report published by World Health Or. (WHO) on February 3, 2022, the leading cause of death is cancer accounting for around 10 million deaths in 2020.

The global  transdermal skin patches market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The growing funding and investments for drug development and new launches boost the growth of market growth. For instance, in September 2021, ImQuest Biosciences has announced the launch of an antiretroviral (ARV) transdermal delivery patch. Simialry, in Feb 2020, the US FDA approved the Contraceptive Patch known as Twirla Transdermal System by Agile Therapeutics Inc. Twirla (levonorgestrel and ethinly estradiol) is a combination of the female hormones progestin and estrogen which is used as a method of contraception for use in women of reproductive potential with a BMI less than 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. 

The global lutein and zeaxanthin market is anticipated to grow a considerable CAGR during the forecast period. Key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in April 2019, Dohler Group acquired the majority of shares in Zumos Catalano Aragoneses S.A (ZUCASA).

The global internal analgesic tablet market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). The factors that drive the market include technological advancement, enhancing research and development activities, and growing awareness of various types of analgesics. For instance, in August 2021, Dr. Reddy’s Laboratories announced the re-launched of over-the-counter Naproxen Sodium Tablets USP, 220 mg in the US market. The drug is the store-brand equivalent of Bayer HealthCare’s Aleve. It is used as a pain relief. In August 2020, Arjuna Natural launched Rhuleave-K, a proprietary botanical formula clinically validated to provide safe pain relief with efficacy and speed equivalent to common OTC medications such as acetaminophen (paracetamol).

The global fexofenadine hydrochloride (HCL) market is anticipated to grow at a considerable CAGR during the forecast years. The antihistamine fexofenadine HCL is used to treat seasonal allergic rhinitis and urticaria. Seasonal allergic rhinitis is an allergic reaction that occurs when the seasons or weather change at least once a year. A runny or stuffy nose, itchy or watery eyes, sneezing, and other symptoms are experienced by the patient. The demand for fexofenadine HCL medications to treat seasonal allergic rhinitis is anticipated to rise as the number of patients suffering from the condition grows. Fexofenadine HCL is an H1 blocker that works by preventing histamines from binding to the H1 receptor. 

The global Pigmented villonodular synovitis drug market is anticipated to grow at a considerable CAGR during the forecast period. The R&D department of companies is working to make new drug therapy for Pigmented villonodular synovitis. Clinical trials are being done by pharma companies for successful inhibitors of Tenosynovial Giant Cell Tumor. This market is expected to rise in the forecasted period as at present many drugs are in their trial phase and yet they are not approved. They are yet to be launched in the market. For instance, in Act 2021, a drug named Vimseltinib (DCC-3014) was found promising and showed efficacy which was given to patients of Tenosynovial Giant Cell Tumor. 

The global bio-based & synthetic polyamide market is anticipated to grow significantly at a CAGR of 3.8% over the forecast period (2022-2028). The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2021, Arkema announced the construction of a polyamide 11 powders plant in China., as they are widely used in demanding applications and provide an innovative solution for fast-growing markets such as, consumer, industrial, and electronic & electric markets.  

The global cough medicine market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). The major factor for the growth of the market during the forecast period is the rising geriatric population as they are more prone to cough and cold. According to the United Nations, the US population in 2018 was 46.7 million, with roughly 17.5 percent of the population aged 65 and up.